Most Active Stories
- Grizzly Bear That Traveled 5,000 Miles Across Idaho, Montana Is A Mystery To Biologists
- Data Points To Early Signs Of An Ada County Housing Bubble
- Idaho Paraglider Could Be National Geographic's Adventurer Of The Year
- Why Idaho Has Largest Share Of Unauthorized Immigrants Impacted By Obama Action
- TV On The Radio To Headline Boise's Treefort Music Fest, Ticket Prices Increase
Tue May 8, 2012
Idaho, Other Northwest States Net Millions From Pharmaceutical Settlement
Idaho, Washington and Oregon are among the 44 states splitting a $100 million settlement with pharmaceutical giant Abbott Labs. The agreement announced Monday resolves a dispute over the company's marketing of a drug called Depakote.
The medication is federally-approved to treat certain mental illnesses. But a multi-state investigation found that Abbott used a flawed study to promote the drug as a way to treat other illnesses, such as schizophrenia and dementia.
"When they subsequently did a second study, that study found that Depakote was not effective to treat schizophrenia," says David Hart a prosecutor with the Oregon Department of Justice. "But they continued to promote using the weaker first study."
The settlement is part of a much larger $1.5 billion deal that Abbott Labs struck with the federal government. It resolves civil and criminal penalties relating to Depakote. In a statement the drug company said it cooperated fully during the investigation.